JPMorgan downgraded Karuna Therapeutics (KRTX) to Neutral from Overweight with a price target of $330, up from $217, after Bristol Myers (BMY) agreed to buy the company for $330 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KRTX:
- Karuna downgraded, Arm target raised: Wall Street’s top analyst calls
- M & A News: Bristol-Myers Squibb (NYSE:BMY) to Buy RayzeBio for $4.1B
- Karuna deal favorable for Axsome Therapeutics, says H.C. Wainwright
- Reviva may be most undervalued in neurology, says H.C. Wainwright
- Karuna Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
